ABL1 is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain ABL1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

AFF1 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain AFF1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 3 are phase 2 (3 open) [3].

ASXL1 is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain ASXL1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

BCOR is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains BCOR status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

BCR is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain BCR status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

CBL is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains CBL status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

CEBPA is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains CEBPA status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

CREBBP is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain DEK status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

ELL is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain ELL status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 2 are phase 2 (2 open) [3].

ETV6 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

EZH2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains EZH2 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 5 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 5 are open and 0 are closed. Of the trials that contain FLT3 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [3].

HIP1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains HIP1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KIT status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 6 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 6 are open and 0 are closed. Of the trials that contain KMT2A status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 5 are phase 2 (5 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

MECOM is an inclusion eligibility criterion in 10 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 10 are open and 0 are closed. Of the trials that contain MECOM status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 9 are phase 2 (9 open) [3].

MLF1 is an inclusion eligibility criterion in 5 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 5 are open and 0 are closed. Of the trials that contain MLF1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 5 are phase 2 (5 open) [3].

MLLT1 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain MLLT1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 2 are phase 2 (2 open) [3].

MLLT10 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain MLLT10 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 2 are phase 2 (2 open) [3].

MLLT3 is an inclusion eligibility criterion in 3 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain MLLT3 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 3 are phase 2 (3 open) [3].

MLLT4 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain MLLT4 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 2 are phase 2 (2 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 7 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 7 are open and 0 are closed. Of the trials that contain NPM1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 7 are phase 2 (7 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 2 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 2 are open and 0 are closed. Of the trials that contain NRIP3 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 2 are phase 2 (2 open) [3].

NUP214 is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain NUP214 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

PBX1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains PBX1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

PRDM16 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

PTPN11 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains PTPN11 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

RIT1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains RIT1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 10 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 10 are open and 0 are closed. Of the trials that contain RPN1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 9 are phase 2 (9 open) [3].

RUNX1 is an inclusion eligibility criterion in 5 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 5 are open and 0 are closed. Of the trials that contain RUNX1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (4 open) [3].

SF3B1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains SF3B1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

SRSF2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains SRSF2 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 4 clinical trials for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 4 are open and 0 are closed. Of the trials that contain TP53 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

U2AF1 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains U2AF1 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].

ZRSR2 is an inclusion eligibility criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains ZRSR2 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open) [3].